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Abstract
Background: Potentially inappropriate prescribing (PIP) in older people is common in primary care and can result
in increased morbidity, adverse drug events, hospitalizations and mortality. The prevalence of PIP in Ireland is
estimated at 36% with an associated expenditure of over €45 million in 2007. The aim of this paper is to describe
the application of the Medical Research Council (MRC) framework to the development of an intervention to
decrease PIP in Irish primary care.
Methods: The MRC framework for the design and evaluation of complex interventions guided the development of the
study intervention. In the development stage, literature was reviewed and combined with information obtained from
experts in the field using a consensus based methodology and patient cases to define the main components of the
intervention. In the pilot stage, five GPs tested the proposed intervention. Qualitative interviews were conducted with
the GPs to inform the development and implementation of the intervention for the main randomised controlled trial.
Results: The literature review identified PIP criteria for inclusion in the study and two initial intervention components -
academic detailing and medicines review supported by therapeutic treatment algorithms. Through patient case studies
and a focus group with a group of 8 GPs, these components were refined and a third component of the intervention
identified - patient information leaflets. The intervention was tested in a pilot study. In total, eight medicine reviews
were conducted across five GP practices. These reviews addressed ten instances of PIP, nine of which were addressed
in the form of either a dose reduction or a discontinuation of a targeted medication. Qualitative interviews highlighted
that GPs were receptive to the intervention but patient preference and time needed both to prepare for and conduct
the medicines review, emerged as potential barriers. Findings from the pilot study allowed further refinement to
produce the finalised intervention of academic detailing with a pharmacist, medicines review with web-based
therapeutic treatment algorithms and tailored patient information leaflets.
Conclusions: The MRC framework was used in the development of the OPTI-SCRIPT intervention to decrease the level
of PIP in primary care in Ireland. Its application ensured that the intervention was developed using the best available
evidence, was acceptable to GPs and feasible to deliver in the clinical setting. The effectiveness of this intervention is
currently being tested in a pragmatic cluster randomised controlled trial.
Trial registration: Current controlled trials ISRCTN41694007
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Background
Potentially inappropriate prescribing (PIP) is a term used
to describe a number of suboptimal prescribing prac-
tices, particularly the use of medicines that introduce a
greater risk of adverse drug-related events where a safer,
as effective alternative is available to treat the same con-
dition [1]. PIP is common in older people and can result
in increased morbidity, adverse drug events, hospitaliza-
tions and mortality [2-4]. PIP is usually measured using
either explicit (criterion-based) or implicit (judgment-
based) tools. Using a recently developed explicit process
measure, the Screening Tool of Older People’s Prescrip-
tions (STOPP) criteria, the prevalence of PIP in older
people (aged ≥ 70 years) in Ireland has been estimated at
36%, associated with an expenditure of over €45 million
in 2007 (or 9% of expenditure on pharmaceuticals in
that age group) [5]. Studies have reported a prevalence
of 35% to 47% in hospitalized older patients [6,7] and
73% in nursing homes [8]. The clinical and economic
burden of PIP is therefore an important public health
concern and it is important to minimize PIP where
possible to increase patient safety and encourage cost-
effective prescribing behaviour.
Changing prescribing behaviour such as PIP, is a com-
plex and challenging task. Several strategies have been
used to alter prescribing practices with variable results,
with no one interventional strategy proving to be con-
sistently effective [2,9-11]. Multifaceted interventions
combining a number of techniques within an interven-
tion [10], may be more effective than any one single
intervention in altering prescribing as multiple elements
can target different aspects of behaviour [2,12,13]. Multi-
faceted interventions are complex interventions, involv-
ing multiple targets (e.g. patients, clinicians) and various
active components that may act both independently and
interdependently [14,15]. In targeting PIP, the impact of
multifaceted interventions to date has been mixed
[9,10,16]. However, such approaches are still widely used
to address prescribing in research. As complex interven-
tions can be difficult to define and develop, the United
Kingdom Medical Research Council (MRC) published a
framework to guide researchers in this task [15]. Initially,
this framework followed a five phase, linear approach.
This has subsequently been updated to be more flexible,
reflecting that research on the context, the intervention
and the evaluation may be conducted simultaneously ra-
ther than sequentially [14,17]. In the revised framework,
the development stage aims to gain an understanding of
the problem, the intervention and the evaluation. Both
feasibility testing and piloting are used to identify key
uncertainties of the study design prior to the full ran-
domised control trial (RCT) such as acceptability, com-
pliance, feasibility and delivery of the intervention and
recruitment and retention. Once the underlying problem
has been examined and a credible intervention devel-
oped, the definitive trial may be undertaken to deter-
mine the effectiveness of the intervention and plans for
future implementation put in place.
Methods
The aim of this paper is to describe the application of
the early stages of the MRC framework to the develop-
ment of a multifaceted intervention aimed at reducing
PIP in Irish primary care. The specific methods and re-
sults of each of the stages of the MRC framework are
presented separately, in sequence. In the development
stage, literature was reviewed and combined with infor-
mation obtained from experts in the field using a con-
sensus based methodology and patient cases to define
the main components of the intervention. In the pilot
stage, five GPs tested the proposed intervention. Quali-
tative interviews were conducted with the GPs to inform
the development and implementation of the intervention
for the main randomised controlled trial. NVivo was
used to assist with organizing the data for analysis. The
aims and methods used are summarised in Table 1. The
development and pilot process is summarised in Figure 1.
The wider effectiveness and acceptability of the interven-
tion is currently being tested in the OPTI-SCRIPT study
(OPTImizing PreSCRIbing for Older People in Primary
Care, a clusTer randomized controlled trial) which is de-
scribed in detail elsewhere [18].
Results
Development phase
The development phase was aimed at understanding the
problem, the evidence to support intervention develop-
ment and the evaluation, through reviewing the existing
literature, identifying theory and modelling processes
and outcomes.
Evidence base and theory
A literature search was conducted to identify PIP criteria
and the empirical and theoretical evidence relating to
intervention research and altering prescribing practice
(initially conducted in October 2011 and updated in
February 2012). Pubmed, EMBASE, the Cochrane
Library of Systematic Reviews and Web of Knowledge
were searched and ‘grey literature’ was searched using
SCIRUS and Lenus. Combinations of MeSH terms and
keywords were used, including inappropriate prescribing;
appropriate prescribing; older people; aged; elderly;
controlled clinical trials as topic; intervention studies;
prescribing interventions; primary care. Additional pub-
lications were identified by a manual search of the refer-
ence lists of relevant studies and review articles. No time
period was applied but the search was limited to English
language and human studies.
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The PIP literature was used to select PIP criteria, as
described in the modelling section below. In terms of
interventions to alter prescribing practices, several strat-
egies have been used with variable results. These include
academic detailing, computerised decision support sys-
tems (CDSS), audit and feedback, the use of multi-
disciplinary teams, and interventions by pharmacists
conducting a medicines review [10,19-23]. These indi-
vidual interventions have shown mixed results in im-
proving the quality of prescribing in older patients and
where they are effective, the effect sizes tend to be small
to modest. Multifaceted interventions, an approach
which combines a number of techniques within a single
intervention [10], may be more likely to work than any
one single intervention in altering prescribing as mul-
tiple elements can target different aspects of behaviour
[2,12,13]. In targeting PIP, the impact of multifaceted
interventions to date has been mixed [9,10,16]. However,
such approaches are still widely used to address pre-
scribing in research.
The use of behavioural theory has also been highligh-
ted as an important factor in designing interventions
[15]. Despite a large body of literature on behaviour
change theory, no single theoretical model has been
universally accepted and the theoretical underpinnings
of interventions are not consistently described and
operationalised in the literature [14,24]. Some question
the usefulness of such theory in intervention design.
Bhattacharyya et al. question the lack of clarity as to
how to translate theory reliably into intervention design
and why any one theory should be given primacy over
another [25], while Oxman et al. argue that less rather
Table 1 Summary of aims and methods
Process Aims Methods
Identifying the evidence
base and theory
To explore the empirical and theoretical
evidence relating to PIP and interventions
and identify intervention components
Literature search of selected
databases and literature review
Modelling To identify PIP criteria to include in the study Consensus based methodology
To identify alternative treatment options Consensus based methodology
Testing components of the intervention with GPs Patient case studies
Testing patient identification mechanism Patient case studies
Assessing GP perspectives on intervention Focus group
Pilot To test the intervention GPs conducting medicines review
To evaluate GP perspectives on intervention Semi-structured interviews with GPs
Development 
Literature review 
• PIP criteria 
identified 
• Algorithms 
created
• Academic 
detailing and 
medicines review 
identified  
Development
Patient case studies 
and focus group
• Patient 
recruitment 
mechanism tested 
and refined
• Algorithms 
refined
• Website 
development 
• Patient 
information 
leaflets added
Pilot with patients 
• Algorithm content 
and structure 
refined 
• Website refined 
• Academic 
detailing and 
medicines review 
tested and refined 
RCT
Figure 1 Flowchart of intervention development adapted from MRC framework. Abbreviations – PIP (Potentially Inappropriate Prescribing);
RCT (Randomised Controlled Trial).
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than more focus is needed on theory [26]. Work is
on-going to develop a universally agreed method of spe-
cifying intervention components aimed at changing
behaviour [27]. In the absence of clear guidance in the
application of theory in intervention research, it is useful
to have a framework for organising the factors that may
influence changes in clinical behaviours. One such
model identified in the literature was the PRECEDE-
PROCEDE model. This is a planning model which
organises the influencing factors into three categories –
predisposing factors, enabling factors and reinforcing
factors [28]. The PRECEDE model was used to organise
the evidence from the literature - predisposing factors
included GP knowledge of PIP, awareness of PIP and
PIP criteria, and belief in value of PIP criteria. Enabling
factors included GP learning, resources available to GP,
GP time, patient expectation and reinforcing factors re-
lated to available incentives such as feedback of research
findings and participation in continuing professional de-
velopment programmes.
From the evidence base, two initial intervention com-
ponents were identified. The first was academic detailing
to address GP knowledge of PIP and PIP criteria, which
was identified in the literature as an important barrier to
appropriate prescribing [29]. The second was conducting
a medicines review which has been identified as a strat-
egy to address PIP [10,30,31]. Pharmacists were identi-
fied as the best candidate to facilitate the academic
detailing with GPs to provide both education on PIP and
advice and support to enable GPs conduct medicines
reviews [23,32,33]. The form and content of these com-
ponents was conceptualised and expanded through the
modelling process.
Modelling
The MRC guidelines recommend the use of both quanti-
tative and qualitative methodologies in the design and
evaluation of an intervention. Qualitative methods can
contribute in several ways to the design and refinement
of an intervention by identifying intervention compo-
nents in need of further refinement, barriers or facilita-
tors to implanting an intervention and involving users in
the development process [34,35]. In this research, qualita-
tive research methods contributed to the refinement of the
intervention through the use of a focus group during mod-
elling and semi-structured interviews in the pilot stage.
During the modelling stage, the findings from the lit-
erature were combined with information obtained from
experts in the area, including general practitioners
(GPs), pharmacists and a specialist in clinical pharma-
cology and medicine for the elderly, firstly using a
consensus-based methodology and secondly, using pa-
tient case studies followed by a focus group, both of
which are described below. These processes allowed us
to identify PIP for inclusion in the study and alternative
therapy options. It also allowed us to test the acceptabil-
ity of components of the intervention with GPs and
provided the opportunity to test methods of patient
identification and recruitment.
Consensus-based methodology – selecting PIP criteria
and alternative treatment options
A preliminary list of individual PIP criteria for inclusion
in the study was compiled from the most commonly
cited existing published criteria, as identified from the
literature search. These included the Beers criteria [36],
the STOPP criteria [37], The McLeod criteria [38], the
Improving Prescribing in the Elderly Tool (IPET), [39]
the Assessing Care of the Vulnerable Elder (ACOVE)
[40], and the Prescription Peer Academic Detailing (Rx-
PAD) study (see Table 2 for summary of these criteria)
[41]. Duplicate criteria were removed from the list and
the prevalence of each individual PIP criteria in Ireland
was sourced from the literature where available. The ini-
tial list consisted of 122 individual criteria. A total of 42
criteria were removed as not being applicable to the
Irish setting (i.e. where specific medications were un-
available and not being considered to be an absolute
contra indication as per the British National Formulary
(BNF) or Irish Medicines Formulary (IMF)) resulting in
a list of 80.
A panel consisting of two GPs (TF, SS), two pharma-
cists (CH, MB) and a physician (DC) was convened by
the research manager (BC). In the first round, the list of
80 PIP criteria was circulated to the panel for indepen-
dent assessment as to which criteria were suitable for
inclusion in this study. The inclusion criteria were:
 Prevalence of indicator
 Clinical significance of indicator
 Evidence base to support inclusion.
The independent reviews were cross-referenced by the
research manager and 24 criteria with complete agree-
ment from all reviewers were included. For example, all
reviewers agreed on the inclusion of “Proton Pump In-
hibitor (PPI) for peptic ulcer disease at full therapeutic
dosage for >8 weeks”. A total of 31 were excluded. The
remaining 25 were re-evaluated in a number of round-
table discussions, until full consensus was achieved
amongst the group on whether to include or exclude the
indicator. From this 25, a further 15 criteria were in-
cluded, resulting in a list of 39 (see Figure 2).
Appropriate alternative treatment options for each of
the selected PIP criteria were identified in the same
manner. Initial pharmacological and non- pharmaco-
logical treatment alternatives were identified from a re-
view of the current evidence-base which was carried out
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by a physician (DC) and a pharmacist (MB). Sources
such as Clinical Evidence, IMF, BNF, and the National
Institute for Health and Clinical Excellence (NICE) were
consulted in this process. The recommended alternatives
were circulated to members of the panel and the ration-
ale and clinical suitability of each was discussed and
reviewed in a number of round table discussions. Where
consensus could not be reached amongst the team, or
where no appropriate alternative was located, a clinical
pharmacologist with an interest in prescribing in older
people (DW) was consulted. This process was on-going
until full consensus was reached amongst the study team
on which pharmacological and non-pharmacological alter-
natives to include. For all of the 39 criteria, a therapeutic
alternative was identified, with non-pharmacological alter-
natives being identified for 12. This process was on-going
over the period of February to September 2011.
Items within the same drug class were grouped into
categories, 18 in total. For example, all criteria relating
to the use of nonsteroidal anti-inflammatory drugs
(NSAIDs) were grouped together. Therapeutic treatment
algorithms were compiled, outlining the particular in-
stance of PIP, the reason for concern and the alternative
therapy option in each case.
Patient case identification
Patient cases were used to test the intervention materials
compiled during the consensus methodology stage and
also to test mechanisms for patient identification. A con-
venience sample of eight GPs working in a variety of
different general practices, involved in a local continuing
medical education (CME) discussion group agreed to
participate.
To test the patient identification mechanism, GPs were
requested to identify five patients (to minimise work-
load) aged 70 and over from their practice who were
taking at least seven repeat prescription items (as
polypharmacy is a risk factor for PIP) [5], and print off
an anonymised prescription summary for each, detailing
medications and diagnoses, prior to a scheduled meeting
date. The anonymised prescription summaries were
given to the research pharmacist (MB) to review and
identify instances of PIP as per those agreed upon dur-
ing consensus-based methodology. From testing this
mechanism, we decided to reduce the inclusion criteria
from seven to two repeat items as this increased the
pool of potential patients.
In total, 23 cases (who had seven repeat medications)
were identified as having at least one PIP. At the CME
meeting, all GPs were given a copy of all 23 cases and
asked to conduct a hypothetical medicines review of
each case using the therapeutic treatment algorithm.
The participants recorded the actions they would have
taken in each case, and why, and commented on the val-
idity/ relevance of the recommended alternatives, using
specifically designed evaluation sheets.
Table 2 Summary of selected PIP criteria
Criteria Year Country of
origin
Number of
criteria
Target group Method of development
McLeod 1997 Canada 38 General population≥ 65 Delphi consensus method
IPET 2000 Canada 14 General population≥ 70 Based on McLeod, validated
in a geriatric unit
Beers 2003* USA 68 General population≥ 65 Delphi consensus method
Rx-PAD 2006 Norway 14 General population≥ 70 years Based on literature and
Delphi consensus method
ACOVE 2007 USA 392 Community- dwelling≥ 65 at greater
risk of death/functional decline
Delphi consensus method
STOPP 2010 Ireland 65 General population≥ 65 Delphi consensus method
* Note: The Beers criteria were first developed in 1991 and updated in 1997, 2003 and most recently in 2012. The 2003 version was included in this study.
Figure 2 PIP criteria review process. Abbreviations – BNF (British National Formulary); IMF (Irish Medicines Formulary).
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During this process, a total of 31 potentially inappro-
priate prescriptions were addressed, across nine medica-
tion groups. The most common indicator identified was
the use of PPIs at full therapeutic dosage for >8 weeks
(29%). The GPs were all in agreement that the PPI in-
dicator, indictors pertaining to NSAIDs, the use of
long-acting benzodiazepines and therapeutic duplication
were all clinically significant. There was debate over the
clinical significance of other indictors relating to the use
of tricyclic antidepressants (TCAs) and bladder anti-
muscarinics (see Table 3).
Focus group
Directly after conducting the hypothetical patient re-
views, participating GPs also took part in a focus group
to evaluate the materials. The topic guide focused on the
chosen PIP drugs, the recommended alternatives and the
decisions the participants would have taken in the clin-
ical setting. The focus group was facilitated by two of
the research team (MB and BC) and was audio-recorded.
The recording was transcribed verbatim and analysed
using a thematic analysis.
The focus group highlighted that participants were
supportive of the study rationale and there was a general
agreement that it was “very important to do this type of
research from a safety point of view.” P1
The participants reported that the therapeutic treat-
ment algorithms were very useful and that structured
provision of concise information was “much more effect-
ive than reams of guidelines.” P2
They provided comments on which areas of the algo-
rithms needed to be formatted differently to be clear
and concise. Consistent with the evaluation sheets, there
was some debate between the participants over the
inclusion of certain criteria and over some of the
recommended alternatives. In particular, the participants
felt that there needed to be more focus on the provision
of non-pharmacological alternative advice in the algo-
rithms: “I think some of the recommendations didn’t, eh,
weren’t, comprehensive enough, didn’t look at non-drug
things.” P1
Patient preference for specific medications was men-
tioned a number of times as being a concern for the par-
ticipants, regardless of whether or not they thought a
problem was clinically significant and it was noted that
GPs found it difficult to do a hypothetical review. They
anticipated that it could be difficult to convince patients
to change a medication and highlighted that there
needed to be a strong clinical basis to support altering
the medications:
“…have to be able to say to them, by being on this you
have an increased risk of whatever.” P2. In light of
this, it was suggested that it would be useful to have
information to give to the patients: “… it’s a good way
of helping people, it’s a good negotiating thing, here’s
the information…” P6
Table 3 Summary of patient cases
Drug/drug group Agreement on
clinical significance
Most common
actions taken
Other comments
PPI Yes Reduce dose While it is clinically significant,
it is also a cost control concern
Stop medication
Corticosteroids Yes Add medication
Long-term, long-acting benzodiazepines Yes Switch to alternative Patient preference is an important factor.
Availability of other services such as cognitive
behavioural therapy is an important factorReduce dose
NSAID Yes Stop medication
Switch to alternative
Bladder antimuscarinics No Leave unaltered Patient preference is an important factor.
Lack of good alternative options available
Switch to alternative
Tricyclic anti-depressants No Leave unaltered Patient preference is an important factor
Switch to alternative
Reduce dose
Therapeutic duplications Yes Stop medication
Switch to alternative
Calcium channel blocker No Switch to alternative
Theophylline Yes Stop medication
Abbreviations: NSAID Nonsteroidal anti-inflammatory drug, PPI Proton pump inhibitor.
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Intervention refinement
The information from the evaluation sheets and the
focus group was compiled and revisions were made to
the format of the materials. Any of the PIP criteria and
alternatives that were debated during the modelling
process were discussed again by the research team and a
decision on whether to retain or remove the criteria was
made. A total of 34 PIP criteria were included in the final
list (see Additional file 1 for a full list of the included
and excluded criteria) and the treatment algorithms were
edited. The finalised algorithms for each PIP medication
group were compiled into a manual of treatment algo-
rithms. A web-based platform was also developed. Ini-
tially, the website was designed as a resource where GPs
could access study information such as the complete
manual of treatment algorithms and outcome forms to
return to the research team. The website underwent a
number of subsequent iterations and became central to
the intervention and is described below in more detail.
GPs expressed that having information to give to pa-
tients would be a useful negotiation tool when it came
to discussing medications with patients. The literature re-
view highlighted that patient information leaflets may be
helpful in improving patient outcomes and that older pa-
tients appreciate being provided with brief, clearly written
information leaflets in addition to verbal information from
their doctor [42]. As a result, patient information leaflets
were developed for the study by the research team (with-
out input from patients). Each leaflet was written in clear
and simple language and described what the medication
was, why the GP may wish to change the medication and
what the alternative treatment alternatives were (see
Figure 3 for example). The leaflets were tested with non-
clinical researchers to check for clarity and readability.
The findings from the literature were combined with
the results from the modelling work to identify the
components of the pilot intervention:
1. Academic detailing with a pharmacist
2. Medicines review with web-based treatment algorithms
3. Patient information leaflets tailored to provide
specific information for each PIP
Figure 3 Example of patient information leaflet.
Clyne et al. BMC Health Services Research 2013, 13:307 Page 7 of 12
http://www.biomedcentral.com/1472-6963/13/307
Piloting
The combination of the evidence base and expert opinion
in the development stage led to the formatting of the pilot
intervention which was tested in the pilot. Five of the
CME group GPs agreed to test the intervention material
in a real practice setting with a selection of the patients
identified previously as having a PIP. The research
pharmacist instructed the GPs on the review process and
the use of the therapeutic treatment algorithms. The GPs
obtained consent from the patients and conducted a real
life medicines review using the intervention materials. GPs
provided written details of the outcome of the review and
participated in a short (5–10 minutes) qualitative semi-
structured interview with the study manager (BC). The in-
terviews were audio-recorded, transcribed and a thematic
analysis conducted.
A total of 13 patients were invited to take part in the
pilot and eight patients consented. Of the five who did
not consent, only one refused to take part while the
others were unavailable to take part at the time (e.g. had
been hospitalised, moved to a nursing home or subse-
quently died).
During the pilot, eight medicines reviews were con-
ducted, in which a total of ten instances of PIP were
addressed, across seven medication groups. Nine out of
the ten instances were addressed in the form of either a
dose reduction or a discontinuation of a targeted medi-
cation. In one case, the prescription was unaltered due
to patient preference. More details on the outcomes of
the reviews are presented in Table 4. One GP conducted
the review successfully over the telephone with the pa-
tient. Previously, the research team had not considered
this approach but it was an interesting outcome of the
pilot.
Participant response to the intervention process
The qualitative evaluation of the pilot study indicated
that GPs were very positive about both their experience
and the patients’ feedback of the review process, and
GPs were motivated to alter their prescribing practice:
“O ya, and she was delighted, I stopped some of her
other medications because she was in front of me and
I had a bit of time to do it.” P5.
GPs were also very receptive to the intervention itself:
“No, I think, I mean, I hope it will be really useful for
GPs, I would certainly like it for myself as a GP so
that’s the best you can say…” P4.
GPs in the pilot did not provide feedback on the aca-
demic detailing, the finalized content was tested with a
GP independent of the focus group to ensure it was
clear and informative.
Participant response to the intervention structure
As in the development stage, it was emphasised that be-
ing concise with information was essential:
“I think in terms of structure, it was better to tailor it
more to individual PIPs.” P6
From the development stage, it emerged that patient
information leaflets may be helpful when it came to ne-
gotiating patient preference. During the pilot, the patient
information leaflets were not entirely successful. While
GPs were very pleased to have them, the patients did
not necessarily always value them:
“She wasn’t interested in the information leaflet at all,
she was just delighted to stop, so she didn’t take the
leaflet home with her at all!” P5
One GP forgot to use the leaflets, highlighting that
leaflets needed to be made more visual to the GPs on
screen as a reminder to use them and that the academic
detailing process should reinforce their use.
Barriers identified by participants
Some potential barriers were also identified. GPs felt
that the extra time required before seeing the patient to
prepare for conducting the review may be an issue, as
Table 4 Pilot study – outcomes of medicines review
Patient PIP Outcome of review
1 PPI Dose reduction
TCA and CCB TCA discontinued
2 PPI Dose reduction
Therapeutic duplication -
ACE and ARB
ARB discontinued
3 Long term long acting
benzodiazepine
Dose reduction
4 PPI Dose reduction
5 Bladder antimuscarinics
and constipation
Left unaltered
6 NSAID and diuretic NSAID discontinued
7 NSAID and ACE NSAID discontinued
8 Long term steroid for maintenance
therapy in COPD/Asthma
Switched from steroid
to other treatment
Abbreviations: ACEI Angiotensin-converting-enzyme inhibitor, ARB Angiotensin
II receptor blockers, CCB Calcium channel blocker, COPD Chronic obstructive
pulmonary disease, NSAID Nonsteroidal anti-inflammatory drugs, PPI Proton
pump inhibitor, TCA Tricyclic anti-depressant.
Note: The decision on whether to follow the recommended treatment alternatives
will be at the discretion of the GP, weighing up the risks and benefits and
patient preference.
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this involved determining why the prescription had been
initiated and by whom:
“I mean it is time consuming which will be the biggest
challenge… it’s nearly a bit of detective work going on,
through the notes, trying to work out how did somebody
on 16 items get onto some of these drugs.” P4
Patient preference was another important limiting fac-
tor identified by GPs:
“When I said initially we wanted her to come off it,
she said, oh no, I’ve been on that for ages, and I don’t
want to come off it.” P2
The finalised intervention
Based on the findings from the development process
and pilot, the pilot intervention was redesigned and the
finalised intervention consisted of academic detailing
with a pharmacist, medicines review with web-based
therapeutic treatment algorithms and tailored patient in-
formation leaflets. Table 5 outlines a comparison of the
pilot intervention and the finalised intervention.
Academic detailing with a pharmacist
A research pharmacist visits the intervention practices.
The aim of the academic detailing session is to educate
GPs about the concept of PIP, focusing on the preva-
lence and consequences of PIP in primary care, and
enable them to conduct a medicines review using the
intervention materials.
Medicines review with web-based therapeutic treatment
algorithms
GPs in the intervention arm are conducting a medicines
review with each participant patient. Each GP is given
individual details to log-in during the review. They can
select particular patients on repeat medications who
were identified as having PIP by the research pharmacist
(identified by study ID number only as assigned by
the GP) and view the specific treatment algorithm(s) ap-
plicable to that patient in pdf format. Each treatment al-
gorithm has the following structure:
Section A: The individual PIP with reason for concern
Section B: Alternative pharmacological and non-
pharmacological treatment options
Section C: Background information (where relevant).
Upon completion of the review, the GP is directed to
an outcome form page which presents them with a
number of tick box options and free text fields to record
the outcome of the review. This information is automat-
ically saved to a database for access by the researcher
Table 5 Intervention development
Intervention
component
Intervention stage
Development Pilot Finalised
Academic detailing
with a pharmacist
Small, but potentially important,
and relatively consistent effects
on prescribing [21].
One brief session delivered in pilot,
participants instructed on review
process and treatment algorithms
One session (30 minutes) discussing:
1) PIP
2) Medicines review
3) Web-based therapeutic treatment
algorithms
Medicines review
with web-based
therapeutic
treatment
algorithms
Medicines review identified as a
strategy to address PIP [10,28,29].
Pharmacists have role in providing
advice and support to enable GPs
conduct medicines reviews [30,31].
Structure of treatment
algorithms revised
One review per patient conducted using
web-based platform which guides
GP through process
Non-pharmacological alternatives
added where applicable
Each treatment algorithm
has the following structure:
Barriers of patient preference
and time highlighted
1) The individual PIP with
reason for concern:
PIP criteria selected
Treatment algorithms to be more
structured More focus on
non-pharmacological alternatives
Structure of web-based
system revised
2) Alternative pharmacological and
non-pharmacological treatment options
3) Background information (where relevant)
Patient information
leaflets
Need for information to give to
patients highlighted
Patient information leaflets developed,
not well utilised in pilot
Patient information leaflets:
1) Describe the PIP and the reasons as to
why it may be inappropriatePatient information leaflets may be
helpful in improving patient outcomes,
older patients appreciate information
leaflets in addition to verbal
information from their doctor [40].
2) Outline the alternative pharmacological and
non-pharmacological therapies GPs may offer.
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team. Once the review outcome form has been filled in,
the medicines review is complete.
Patient information leaflets
For every alternative therapeutic option, a brief patient
information leaflet is available. These leaflets describe
the PIP and the reasons as to why it may be inappropri-
ate. They also outline the alternative pharmacological
and non-pharmacological therapies the GP may offer in-
stead (see Figure 3).
Discussion
It is generally accepted that interventions should be de-
veloped in a systematic way if they are to be feasible and
effective. The purpose of this article was to describe the
application of the MRC framework to the development
of a primary care intervention targeted at reducing PIP.
During the development phase, the pre-existing evidence
on the topic of PIP and intervention research was con-
sidered by an expert panel and a group of participating
GPs to produce a pilot intervention which was then
tested. This process allowed the research team to iden-
tify areas of the intervention and study design that were
in need of further refinement and make the intervention
more acceptable to the target study population.
The consensus panel methodology used in the develop-
ment phase allowed us to select PIP criteria and alterna-
tive treatment options that were prevalent and considered
clinically relevant to Irish primary care. During the model-
ling stage it was recommended that the material be more
concise and there was more emphasis placed on the
addition of non-pharmacological alternatives. The thera-
peutic treatment algorithms were edited to reflect this.
Patient preference for remaining on certain medica-
tions emerged as an important aspect in the develop-
ment stage. Patient information leaflets were compiled
for each of the PIP criteria and recommended alterna-
tives. These leaflets were designed to assist the GP in
discussing individual medications with the patient dur-
ing the medicines review and negotiate changes with
them. The leaflets were not universally valued in the
pilot but were retained in the finalised intervention as
an option for those interested.
Concise information was a key concern of the GPs in-
volved in the modelling process and pilot. With this in
mind, the therapeutic treatment algorithms were edited
and the web-based platform was designed in such a way
that the GPs in the intervention arm would see only the
therapeutic treatment algorithm(s) relevant to each patient,
making the most efficient use of the consultation time.
The pilot interviews highlighted that there may be ‘de-
tective work’ involved in determining why a particular
medication was initiated and by whom. Roughly 30% of
the population in Ireland are entitled to free, State-
funded GP care and medications. Some 38% of prescrip-
tions for these patients have been found to be initiated
by hospital specialists [43]. This highlights concerns
around overall responsibility for the prescription and the
possibility that the GP may not wish to alter or discon-
tinue a hospital-initiated prescription. To capture this
information, an option was incorporated into the out-
come form where the GP could tick if the prescription
was unaltered for this reason.
The use of qualitative research to help refine the inter-
vention was valuable. The focus group and pilot inter-
views helped to anticipate and identify barriers to the
intervention such as patient preference and the import-
ance of being concise with information. Qualitative in-
terviews will also be conducted at the end of the RCT.
We anticipate the qualitative data will provide insight
into the intervention delivery and acceptability of the
intervention to both GPs and patients.
Although the development process enabled us to make
a number of improvements to our intervention, and to
achieve a design that is likely to be accepted in the clin-
ical setting, we were constrained by the research context
in some areas. Through the modelling and piloting, we
were able to test the mechanisms for patient identifica-
tion and recruitment. The initial mechanism used
proved to be quite time consuming and it was proposed
that a member of the research team (BC) would become
a research agent of the practice to speed up the process.
This would also minimize the effort required by the
practice staff to recruit patients, which can improve suc-
cessful recruitment to RCTs [44]. However, the Ethics
Committee requested that the patient consent process
be done by the practices themselves so the method
remained the same as outlined previously.
Conclusion
The MRC framework provided a systematic way of
developing a complex intervention in decreasing PIP in
primary care. It provided the opportunity to identify issues
and aspects of the intervention that required further de-
velopment and the pilot phase indicated that the interven-
tion would be well received by GPs, providing support for
the implementation of the intervention in clinical practice
in Irish primary care. Through the OPTI-SCRIPT study,
we expect to determine the effectiveness and acceptability
of the intervention in clinical practice.
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